Correction: Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results
verfasst von:
Andreas R. Gantenbein, Reto Agosti, Christian P. Kamm, Gunther Landmann, Niklaus Meier, Gabriele Susanne Merki-Feld, Jens A. Petersen, Heiko Pohl, Philippe Ryvlin, Christoph J. Schankin, Dragana Viceic, Chiara Zecca, Elisabeth Schäfer, Ina Meyer, Michael E. Arzt
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Correction: Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results
verfasst von
Andreas R. Gantenbein Reto Agosti Christian P. Kamm Gunther Landmann Niklaus Meier Gabriele Susanne Merki-Feld Jens A. Petersen Heiko Pohl Philippe Ryvlin Christoph J. Schankin Dragana Viceic Chiara Zecca Elisabeth Schäfer Ina Meyer Michael E. Arzt
